Revitalist Enters USD $1B TMS Market
TMS is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of those suffering from depression, Alzheimer’s disease, Parkinson’s disease, and Epilepsy. TMS is typically used when other depression treatments haven't been effective.
Revitalist CEO,
ABOUT
On Behalf of the Board
Chief Executive Officer
For additional information and to be added to the Company’s mailing list, please click here.
Forward Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005101/en/
Investor Relations
IR@revitalist.com
(865) 585-8414
Source: